Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03493789 | Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy | completed | Phase 1 | 19 | Emory UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02897375 | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | completed | Phase 1 | 71 | Emory UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03735628 |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors |
| completed |
| Phase 1 |
| 16 |
| BayerINDUSTRY |
| 2 |
| Oct 6, 2023 |
| clinicaltrials |
| NCT02947386 | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 7 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT00084799 | Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC) | completed | Phase 1 | 10 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00856037 | Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 1 | 22 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT02803203 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02439450 | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 121 | Heat BiologicsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01998529 | Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy | completed | Phase 1 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03953235 | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | completed | Phase 1 / Phase 2 | 39 | Gritstone bio, Inc.INDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT03216343 | Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer | completed | Phase 1 | 48 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT01997190 | Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion(MpeTK01) | completed | Phase 1 | 19 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT03840915 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 70 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Aug 21, 2023 | clinicaltrials |
| NCT04131426 | Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia | completed | Phase 1 | 25 | University of RochesterOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT04601402 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | completed | Phase 1 | 11 | Genome & CompanyINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00107250 | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | completed | Phase 1 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00343408 | AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer | completed | Phase 1 | 31 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00471432 | OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | completed | Phase 1 | 40 | NCIC Clinical Trials GroupNETWORK | 0 | Aug 4, 2023 | clinicaltrials |
| NCT00526461 | Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer | completed | Phase 1 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00869752 | MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 12 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01068587 | MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy | completed | Phase 1 / Phase 2 | 31 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01783197 | Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | completed | Phase 1 | 39 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04012619 | Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer | completed | Phase 1 | 8 | Sichuan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT04959981 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC(HERKULES-2) | completed | Phase 1 | 24 | Erasca, Inc.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03215810 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05026593 | A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 | 60 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03656705 | CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma | completed | Phase 1 | 2 | Henan Medical UniversityOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04695847 | M1231 in Participants With Solid Tumors | completed | Phase 1 | 23 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Jul 7, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05116891 | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Cantargia ABINDUSTRY | 2 | Jul 3, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00003649 | Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed | completed | Phase 1 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
| NCT04672356 | A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer | completed | Phase 1 | 19 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04672369 | A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC | completed | Phase 1 | 42 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | completed | Phase 1 | 36 | Providence Health & ServicesOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT02740985 | A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | completed | Phase 1 | 313 | AstraZenecaINDUSTRY | 1 | May 26, 2023 | clinicaltrials |
| NCT01004731 | Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer | completed | Phase 1 / Phase 2 | 7 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT04541407 | Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease | completed | Phase 1 | 1 | University of Colorado, DenverOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05860582 | A Study of [14C]GB491 in Male Healthy Subjects | completed | Phase 1 | 6 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)(STORM) | completed | Phase 1 | 85 | ViralyticsINDUSTRY | 3 | May 6, 2023 | clinicaltrials |
| NCT03455829 | G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 30 | G1 Therapeutics, Inc.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 18, 2023source: clinicaltrials